The majority of incarcerated adults are parents. While in prison, most parents maintain at least some contact with their families. A positive connection with family during imprisonment is hypothesized to improve long-term success after release. One way in which departments of corrections attempt to facilitate positive connections with family is through prison-based parenting programs. One such program, developed in collaboration with the Oregon Department of Corrections, is the cognitive-behavioral parent management training program Parenting Inside Out (PIO). Outcomes due to PIO were examined within the context of a randomized controlled trial. Incarcerated parents from all correctional facilities in the state of Oregon were recruited to participate, and eligible parents who consented ( = 359) were transferred to participating releasing institutions. After initial assessment, parents were randomized to condition (i.e., PIO "intervention" condition or services-as-usual "control" condition) and then followed through the remainder of their prison sentences and to one year after release. Intervention condition participants were offered PIO prior to their release. Outcomes favoring participants in the intervention condition were found in areas of importance to parents and their children and families and to public health and safety at large, including a decreased likelihood of problems related to substance use and of engaging in criminal behavior during the first six months following release as well as a decreased likelihood of being arrested by police during the first year following release. The implications of the findings are discussed, including the critical need for scientifically rigorous research on multi-component parenting programs delivered during the reentry period.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9030531 | PMC |
http://dx.doi.org/10.3390/ijerph19084605 | DOI Listing |
J Med Internet Res
January 2025
Department of Basic and Community Nursing, School of Nursing, Nanjing Medical University, NanJing, China.
Background: Telehealth interventions can effectively support caregivers of people with dementia by providing care and improving their health outcomes. However, to successfully translate research into clinical practice, the content and details of the interventions must be sufficiently reported in published papers.
Objective: This study aims to evaluate the completeness of a telehealth intervention reporting in randomized controlled trials (RCTs) conducted for caregivers of people with dementia.
JMIR Ment Health
January 2025
Division of Psychology and Mental Health, University of Manchester, Manchester, United Kingdom.
Background: Digital mental health interventions (DMHIs) to monitor and improve the health of people with psychosis or bipolar disorder show promise; however, user engagement is variable, and integrated clinical use is low.
Objective: This prospectively registered systematic review examined barriers and facilitators of clinician and patient engagement with DMHIs, to inform implementation within real-world settings.
Methods: A systematic search of 7 databases identified empirical studies reporting qualitative or quantitative data about factors affecting staff or patient engagement with DMHIs aiming to monitor or improve the mental or physical health of people with psychosis or bipolar disorder.
J Clin Psychiatry
January 2025
Nathan S. Kline Institute for Psychiatric Research, Orangeburg, New York, and Department of Psychiatry, New York University School of Medicine, New York, New York.
There are few established treatments for negative symptoms in schizophrenia, which persist in many patients after positive symptoms are reduced. Oxidative stress, inflammation, and epigenetic modifications involving histone deacetylase (HDAC) have been implicated in the pathophysiology of schizophrenia. Sulforaphane has antioxidant properties and is an HDAC inhibitor.
View Article and Find Full Text PDFJ Clin Psychiatry
January 2025
Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York.
To provide proof-of-concept (PoC), dose-range finding, and safety data for BI 1358894, a TRPC4/5 ion channel inhibitor, in patients with borderline personality disorder (BPD). This was a phase 2, multinational, randomized, double-blind, placebo controlled trial. Patients were randomized to oral placebo or BI 1358894 (5 mg, 25 mg, 75 mg, or 125 mg) once daily in a 2.
View Article and Find Full Text PDFJ Clin Psychiatry
January 2025
Division of Pharmacotherapy and Translational Science, College of Pharmacy, University of Texas at Austin, San Antonio, Texas.
To evaluate weight change with a combination of olanzapine and samidorphan (OLZ/SAM) versus olanzapine by pooling data across clinical studies. This study was an individual patient data (IPD) meta-analysis of clinical trial data. EMBASE, MEDLINE, and PsycInfo were searched for randomized clinical trials (≥12 weeks) in adults with schizophrenia or bipolar I disorder in which weight change from baseline was the primary or secondary end point.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!